Plain-English translation of NCT03037385 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial tested a new cancer medication called pralsetinib in patients with advanced cancers that had genetic changes affecting a protein called RET, or cancers that had stopped responding to standard treatment. The study had two parts: first, researchers tested different doses to find the safest and most effective level, and then they expanded the study to test that dose in larger groups of patients with different cancer types.
Many patients with advanced cancers like lung cancer and thyroid cancer run out of treatment options when standard therapies stop working or cause severe side effects. This medication was designed to specifically target cancers with RET genetic changes, offering hope for patients who previously had limited choices.
Participants took the medication by mouth daily at a dose determined during the study's first phase. They attended regular clinic visits where their doctors monitored how well the medication was working, checked for side effects, and performed blood tests and imaging scans to track their cancer. The study involved both a dose-finding phase where different patients received different amounts of medication, followed by an expanded phase where larger groups received the dose shown to be most effective.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States